MAPT and Alzheimer disease: Interestingly, Ferreiro et al showed GM composition correlated with Aβ and tau pathological biomarkers but not with biomarkers of neurodegeneration by metagenomic sequencing, suggesting that the GM may change early in AD progression [61].